Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as SHAPE
SHP-141C · 1 trial · 1 indication
Measurement of plaque severity including erythema, induration, and desquamation.
| Arm | Type | Description |
|---|---|---|
| SHP-141C & Placebo & Calcipotriol & Betamethasone Valerate | EXPERIMENTAL | A 100 mg dose of SHP-141C cream at three concentrations (0.5%, 1.0% and 2.0%), a matched placebo cream and two reference treatments: Calcipotriol 0.005% cream and Betamethasone Valerate 0.02% cream, applied topically to a selected plaque on each subject, six times per week over 28 days for a total of 24 doses. |
| Name | Type | Description |
|---|---|---|
| SHP-141C | DRUG | Topical Cream |
| Placebo to SHP-141C | DRUG | Placebo Topical Cream |
| Betamethasone Valerate | DRUG | Topical cream, 0.02% |
| Calcipotriol | DRUG | Topical cream, 0.005% |
Inclusion Criteria: 1. Mild to moderate chronic plaque-type psoriasis. 2. psoriasis of at least one year. 3. Stable disease for at least two weeks prior to the commencement of study treatment. 4. One nominated target lesions must have areas of at least 86 x 57 mm2. 5. BMI of less than 35 kg/m2. - ...